The ACTH-(4–9) analog, ORG 2766, prevents taxol-induced neuropathy in rats

doi:10.1016/0014-2999(93)90367-Q

European Journal of Pharmacology

Volume 233, Issue 1, 16 March 1993, Pages 177-178

https://doi.org/10.1016/0014-2999(93)90367-Q Get rights and content

Abstract

Taxol is a novel and promising oncolytic agent the use of which is hampered by its neurotoxity. We now describe a taxol-induced neuropathy in rats and its prevention by the adrenocorticotropic hormone-(4–9) (ACTH-(4–9)) analog, ORG 2766. A decrease in sensory nerve conduction velocity was seen in taxol-treated rats, both with daily injections of small amounts (6 mg/kg per week) and with weekly injections of higher amounts (9 mg/kg per week) of taxol. Concomitant administration of ORG 2766 completely prevented the occurence of a neuropathy.

References (8)

P. De Koning et al.
Evaluation of cis-diamminedichloroplatinum(II) (Cisplatin) neurotoxicity in rats
Toxicol. Appl. Pharmacol.
(1987)
W.H. Gispen
Therapeutic potential for melanocortins in peripheral nerve disease
Trends Pharmacol. Sci.
(1990)
W.H. Gispen et al.
ACTH/MSH like peptides in the treatment of cisplatin neuropathy
J. Steroid Biochem. Mol. Biol.
(1992)
van der Hoop Gerritsen et al.
Prevention of cisplatin neurotoxicity with an ACTH(4–9) analogue in patiens with ovarian cancer
N. Engl. J. Med.
(1990)

There are more references available in the full text version of this article.

Cited by (59)

Involvement of TACAN, a Mechanotransducing Ion Channel, in Inflammatory But Not Neuropathic Hyperalgesia in the Rat
2021, Journal of Pain
Citation Excerpt :
Oxaliplatin was freshly dissolved in normal saline at a concentration of 2 mg/mL just prior to intravenous administration (1 mL/kg), via tail vein injection, in rats anesthetized with isoflurane (2.5% in O2). Paclitaxel was dissolved in absolute ethanol and polyethoxylated castor oil (Cremophor EL; 1:1; Sigma-Aldrich)1,8,16,20 and diluted in saline, to a concentration of 1 mg/mL, just before intraperitoneal (i.p.) injection.15,32 Paclitaxel (1 mg/kg) was administered, every other day for a total of 4 doses, in rats anesthetized with isoflurane (2.5% in O2).
TACAN (Tmem120A), a mechanotransducing ion channel highly expressed in a subset of nociceptors, has recently been shown to contribute to detection of noxious mechanical stimulation. In the present study we evaluated its role in sensitization to mechanical stimuli associated with preclinical models of inflammatory and chemotherapy-induced neuropathic pain (CIPN). Intrathecal administration of an oligodeoxynucleotide antisense (AS-ODN) to TACAN mRNA attenuated TACAN protein expression in rat dorsal root ganglia (DRG). While TACAN AS-ODN produced only a modest increase in mechanical nociceptive threshold, it markedly reduced mechanical hyperalgesia produced by intradermal administration of prostaglandin E₂, tumor necrosis factor alpha, and low molecular weight hyaluronan, and systemic administration of lipopolysaccharide, compatible with a prominent role of TACAN in mechanical hyperalgesia produced by inflammation. In contrast, TACAN AS-ODN had no effect on mechanical hyperalgesia associated with CIPN produced by oxaliplatin or paclitaxel. Our results provide evidence that TACAN plays a role in mechanical hyperalgesia induced by pronociceptive inflammatory mediators, but not CIPN, compatible with multiple mechanisms mediating mechanical nociception, and sensitization to mechanical stimuli in preclinical models of inflammatory versus CIPN.
We evaluated the role of TACAN, a mechanotransducing ion channel in nociceptors, in preclinical models of inflammatory and CIPN. Attenuation of TACAN expression reduced hyperalgesia produced by inflammatory mediators but had not chemotherapeutic agents. Our findings support the presence of multiple mechanotransducers in nociceptors.
Overview of cisplatin-induced neurotoxicity and ototoxicity, and the protective agents
2020, Food and Chemical Toxicology
Cisplatin has dramatically improved the survival rate of cancer patients, but it has also increased the prevalence of hearing and neurological deficits in this population. Cisplatin induces ototoxicity, peripheral (most prevalent) and central (rare) neurotoxicity. This review addresses the ototoxicity and the neurotoxicity associated with cisplatin-based chemotherapy, providing an integrated view of the potential protective agents that have been evaluated in vitro, in vivo and in clinical trials, their targets and mechanisms of protection and their effects on the antitumor activity of cisplatin. So far, the findings are insufficient to support the use of any oto- or neuroprotective agent before, during or after cisplatin chemotherapy. Despite their promising effects in vitro and in animal studies, many agents have not been evaluated in clinical trials. Additionally, the clinical trials have limitations concerning the sample size, controls, measurement, heterogeneous groups, several arms of treatment, short follow-up or no blinding. Besides that, for most agents, the effects on the antitumor activity of cisplatin have not been evaluated in tumor-bearing animals, which discourages clinical trials. Further well-designed randomized controlled clinical trials are necessary to definitely demonstrate the effectiveness of the oto- or neuroprotective agents proposed by animal and in vitro studies.
Neurological complications of chemotherapy to the peripheral nervous system
2012, Handbook of Clinical Neurology
Citation Excerpt :
In animal studies, nerve growth factor attenuated neurotoxic effects of paclitaxel on spinal cord–ganglion explants from mice (Peterson and Crain, 1982), prevented neurotoxicity on rat sympathetic ganglion explants (Hayakawa et al., 1994), and prevented toxic neuropathy in mice in vivo (Apfel et al., 1991). The ACTH 4-9 analog Org 2766 prevented paclitaxel-induced neuropathy in rats in vivo, but not in vitro (Hamers et al., 1993b; Hol et al., 1994). Administration of the cytoprotective agent amifostine (WR 2721) (Spencer and Goa, 1995) with high-dose paclitaxel in patients with advanced cancer showed promising results (Schuchter et al., 1995).
Peripheral neuropathy is a common side‐effect of a number of cytostatic drugs of which vinca‐alkaloids, platinum compounds, and taxanes are the most important. The neuropathies caused by several groups of cytostatic compounds will be reviewed in this chapter. The clinical characteristics, neurophysiological findings, pathogenesis and natural course will be discussed together with several attempts that have been undertaken to ameliorate the neurotoxic effects.
Neurotoxicity of chemotherapy
2010, Blue Books of Neurology
Citation Excerpt :
Pyridoxine may speed recovery in the case of docetaxol, and amitryptiline or gabapentin may be useful if neuropathic pain is significant. Although no neuroprotective agents can be recommended at present, laboratory studies with nerve growth factor,140 ACTH analogues,141 and phase I clinical trials of glutamate and amifostine25 have produced some encouraging results. CNS toxicity is rare, reflecting poor penetrance of the blood-brain barrier, although there have been occasional case reports of paclitaxol precipitating a mild encephalopathy.
Neurological side effects are a common complication following chemotherapy and can adversely affect clinical management of the cancer patient. Cancer patients during chemotherapy report problems with memory retrieval, learning, and concentration, which may persist after treatment has finished or never fully resolve. Peripheral neuropathies are the most common neurological complications in patients receiving chemotherapy, especially with regimens containing taxanes, platinum, and vinca alkaloids. Acute encephalopathy is another common problem in oncology patients; however, encephalopathy because of cytotoxic drug exposure is generally self-limiting and recovers spontaneously. Leukoencephalopathy may follow on from acute encephalopathy, but may also be the first indication of neurotoxicity several months to years after administration of cytotoxic drugs. Neurotoxicity is a frequent and dose-limiting side effect of chemotherapy, and apart from dose reduction or discontinuing the drugs implicated in the development of neurotoxicity, there is very little in the way of specific pharmacological management to reverse their side effects. Search for new anticancer agents has switched away from classical cytotoxics that kill cancer cells by inducing DNA damage to agents that modify growth signaling pathways, and the two main types of agents are the -mabs, which are monoclonal antibodies that target either cell surface receptors or circulating ligand, and the -ibs, which are small drug molecules that target intracellular stages of signaling pathways. These drugs have a much gentler side effect profile compared with cytotoxic agents and very little in the way of neurotoxicity has been reported in the literature to date.
Brain effects of melanocortins
2009, Pharmacological Research
The melanocortins (α, β and γ-melanocyte-stimulating hormones: MSHs; adrenocorticotrophic hormone: ACTH), a family of pro-opiomelanocortin (POMC)-derived peptides having in common the tetrapeptide sequence His-Phe-Arg-Trp, have progressively revealed an incredibly wide range of extra-hormonal effects, so to become one of the most promising source of innovative drugs for many, important and widespread pathological conditions.
The discovery of their effects on some brain functions, independently made by William Ferrari and David De Wied about half a century ago, led to the formulation of the term “neuropeptide” at a time when no demonstration of the actual production of peptide molecules by neurons, in the brain, was still available, and there were no receptors characterized for these molecules.
In the course of the subsequent decades it came out that melanocortins, besides inducing one of the most complex and bizarre behavioural syndromes (excessive grooming, crises of stretchings and yawnings, repeated episodes of spontaneous penile erection and ejaculation, increased sexual receptivity), play a key role in functions of fundamental physiological importance as well as impressive therapeutic effects in different pathological conditions.
If serendipity had been an important determinant in the discovery of the above-mentioned first-noticed extra-hormonal effects of melanocortins, many of the subsequent discoveries in the pharmacology of these peptides (feeding inhibition, shock reversal, role in opiate tolerance/withdrawal, etc.) have been the result of a planned research, aimed at testing the “pro-nociceptive/anti-nociceptive homeostatic system” hypothesis.
The discovery of melanocortin receptors, and the ensuing synthesis of selective ligands with agonist or antagonist activity, is generating completely innovative drugs for the treatment of a potentially very long list of important and widespread pathological conditions: sexual impotence, frigidity, overweight/obesity, anorexia, cachexia, haemorrhagic shock, other forms of shock, myocardial infarction, ischemia/reperfusion-induced brain damage, neuropathic pain, rheumathoid arthritis, inflammatory bowel disease, nerve injury, toxic neuropathies, diabetic neuropathy, etc.
This review recalls the history of these researches and outlines the pharmacology of the extra-hormonal effects of melanocortins which are produced by an action at the brain level (or mainly at the brain level). In our opinion the picture is still incomplete, in spite of being already so incredibly vast and complex. So, for example, several of their effects and preliminary animal data suggest that melanocortins might be of concrete effectiveness in one of the areas of most increasing concern, i.e., that of neurodegenerative diseases.
Erythropoietin protects sensory axons against paclitaxel-induced distal degeneration
2006, Neurobiology of Disease
Paclitaxel causes a sensory polyneuropathy with characteristic features of distal axonal degeneration. Although the exact mechanisms underlying distal axonal degeneration are unknown, paclitaxel-induced axonal degeneration has been shown to be associated with an increase in detyrosinated tubulin. Here we show that recombinant human erythropoietin prevents axonal degeneration in sensory neurons in vitro and this effect is associated with downregulation of detyrosinated tubulin. Furthermore, in an animal model of paclitaxel-induced distal sensory polyneuropathy, recombinant human erythropoietin protects against distal axonal degeneration. These findings suggest that recombinant human erythropoietin may be useful as a therapy to prevent paclitaxel-induced sensory polyneuropathy in patients undergoing chemotherapy.

View all citing articles on Scopus

View full text

Rapid communicationThe ACTH-(4–9) analog, ORG 2766, prevents taxol-induced neuropathy in rats

Abstract

Toxicol. Appl. Pharmacol.

Trends Pharmacol. Sci.

J. Steroid Biochem. Mol. Biol.

Prevention of cisplatin neurotoxicity with an ACTH(4–9) analogue in patiens with ovarian cancer

N. Engl. J. Med.

Rapid communication
The ACTH-(4–9) analog, ORG 2766, prevents taxol-induced neuropathy in rats